Universidad Peruana Cayetano Heredia

Intravenous iron supplementation may protect against acute mountain sickness: A randomized, double-blinded, placebo-controlled trial

Mostrar el registro sencillo del ítem

dc.contributor.author Talbot, N.P.
dc.contributor.author Smith, T.G.
dc.contributor.author Privat, C.
dc.contributor.author Nickol, A.H.
dc.contributor.author Rivera Chira, Maria Concepcion
dc.contributor.author León-Velarde, Fabiola
dc.contributor.author Dorrington, K.L.
dc.contributor.author Robbins, P.A.
dc.date.accessioned 2022-01-18T19:26:50Z
dc.date.available 2022-01-18T19:26:50Z
dc.date.issued 2011
dc.identifier.uri https://hdl.handle.net/20.500.12866/10938
dc.description.abstract Acute mountain sickness (AMS) is a common and disabling condition that occurs in healthy individuals ascending to high altitude. Based on the ability of iron to influence cellular oxygen sensing pathways, we hypothesized that iron supplementation would protect against AMS. To examine this hypothesis, 24 healthy sea-level residents were randomized to receive either intravenous iron(III)-hydroxide sucrose (200mg) or saline placebo, before ascending rapidly to Cerro de Pasco, Peru (4340m). The Lake Louise scoring system was used to assess incidence and severity of AMS at sea level and on the first full day at altitude. No significant difference in absolute AMS score was detected between the two groups either at baseline or at high altitude. However, the mean increase in AMS score was 65% smaller in the iron group than in the saline group (p<0.05), and the change in AMS score correlated negatively with the change in ferritin (R=-0.43; p<0.05). Hematocrit and arterial oxygen saturation were unaffected by iron. In conclusion, this preliminary randomized, double-blinded, placebo-controlled trial suggests that intravenous iron supplementation may protect against the symptoms of AMS in healthy volunteers. en_US
dc.language.iso eng
dc.publisher Mary Ann Liebert
dc.relation.ispartofseries High Altitude Medicine and Biology
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Humans en_US
dc.subject Young |Controlled Study en_US
dc.subject Normal |Disease Severity en_US
dc.subject Altitude en_US
dc.subject Altitude Disease en_US
dc.subject Altitude Sickness en_US
dc.subject Oxygen en_US
dc.subject Randomized Controlled Trial en_US
dc.subject Severity Of Illness Index en_US
dc.subject Acute Disease en_US
dc.subject Human Experiment en_US
dc.subject Hematocrit en_US
dc.subject Sodium Chloride en_US
dc.subject Double Blind Procedure en_US
dc.subject Sea Level en_US
dc.subject Ferric Compounds en_US
dc.subject Iron en_US
dc.subject Injections Intravenous en_US
dc.subject High Altitude en_US
dc.subject Hematocrit en_US
dc.subject Acute Mountain Sickness en_US
dc.subject Arterial Oxygen Saturation en_US
dc.subject Ferric Hydroxide Sucrose en_US
dc.subject Ferritin en_US
dc.subject Hypoxia-Inducible Factor en_US
dc.subject Iron Therapy en_US
dc.subject Sucrose en_US
dc.title Intravenous iron supplementation may protect against acute mountain sickness: A randomized, double-blinded, placebo-controlled trial en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1089/ham.2011.1005
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.03.05
dc.relation.issn 1557-8682


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas